Haematologica, Vol 94, Issue 10, 1375-1382 doi:10.3324/haematol.2009.009217
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Schaefer, E. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schaefer, E. W.

Acute Myeloid Leukemia

A phase 2 study of vorinostat in acute myeloid leukemia

Eric W. Schaefer1, Arturo Loaiza-Bonilla2, Mark Juckett3, John F. DiPersio4, Vivek Roy5, James Slack6, Wenting Wu1, Kristina Laumann1, Igor Espinoza-Delgado7, Steven D. Gore for the Mayo P2C Phase II Consortium

1 Mayo Clinic Cancer Center, Rochester, Minnesota
2 Department of Medicine, Harbor Hospital Center, Baltimore, Maryland
3 University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin
4 Washington University School of Medicine, St. Louis, Missouri
5 Mayo Clinic, Jacksonville, Florida
6 Mayo Clinic, Scottsdale, Arizona, USA
7 Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Md, USA

Correspondence: Steven D. Gore, MD, The Sidney Kimmel, Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 288, Baltimore, Md 21231, USA. E-mail:gorest{at}jhmi.edu

Background: This two-stage, multi-institutional, randomized phase 2 trial assessed the toxicity and response rate associated with two treatment schedules of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid; SAHA) in patients with relapsed acute myeloid leukemia and in selected untreated patients with high-risk acute myeloid leukemia.

Design and Methods: Patients with relapsed or untreated acute myeloid leukemia who were not candidates for chemotherapy entered one of the two treatment arms. In both arms a total dose of 8400 mg of vorinostat was delivered in each 21-day cycle of treatment: in arm A the dose regimen was 400 mg daily whereas in arm B the dose regimen was 200 mg three times daily for 14 days followed by 1 week rest.

Results: Data from all 37 patients were used for the analyses. In arm A (n=15), the confirmed complete remission rate was 0% (95% CI, 0% to 23%); this arm was closed at the planned interim analysis. In arm B (n=22), the confirmed complete remission rate was 4.5% (1 response; 95% CI, 0.4% to 24%), with a duration of response exceeding 398 days. The median time to treatment failure in arm A was 42 days (95% CI, 26 to 57); although a minimum of four cycles of treatment were planned, 11 patients (79%) received no more than two cycles. The median time to treatment failure in arm B was 46 days (95% CI, 20 to 71); 13 patients (59%) received no more than two cycles of treatment.

Conclusions: Vorinostat monotherapy demonstrated minimal activity in this group of patients with acute myeloid leukemia. Therapy was discontinued in many patients before the planned four cycles had been administered, either because of failure of vorinostat to control the leukocyte count or patients’ and physicians’ preference. Future studies of vorinostat in acute myeloid leukemia should focus on combinations with other drugs with which it might interact pharmacodynamically. ClinicalTrials.gov Identifier: NCT00305773.

Key words: acute myeloid leukemia, acute myeloid leukemia, HDAC, histone deacetylase inhibitor, phase 2, SAHA, suberoylanilide hydroxamic acid, vorinostat.